Preparing market rhythm analysis...
News Center
Browse cached source articles used by the rhythm engine. Filter by ticker, sentiment, or keyword, then open the stock rhythm page for deeper daily, swing, and long-term analysis.
Cached Articles
35963
Tickers With News
516
Showing Now
49
Top Ticker
AAPL
Featured Tickers
Jump straight into the most important tickers for testing and market coverage.
Latest Articles
Mounjaro is the first and only GIP and GLP-1 receptor agonist proven to lower heart attack, stroke or cardiovascular death risk in adults with type 2 diabetes at high risk for these events – in addition to its
Eli Lilly and Co. shares are trading lower Wednesday, pulling back from last week's record high despite positive real-world data on Zepbound.
Eli Lilly (LLY) passes the CAN SLIM screen with strong earnings, sales growth, high relative strength, and bullish technicals. Learn more.
For adults over the age of 55, including patients in Medicare's GLP-1 Bridge program, these lower costs translate into meaningful savings as early as 12 months into treatment. This is the first study of its kind in
New Eli Lilly study reveals that Zepbound significantly lowers monthly healthcare costs for older adults with overweight or obesity.
LLY offers a modest 0.75% yield but a sustainable 7/10 dividend rating, 15% annual growth, and a 21.66% payout ratio, backed by strong profitability.
-Reuters
Griffin's Q2 move is already paying off nicely.
Eli Lilly just delivered one of the most staggering quarters in Big Pharma history, yet Wall Street is barely reacting. Three catalysts in the next 18 months could either push shares to levels few analysts dare to print or expose the cracks in a very expensive story.
Eli Lilly (LLY) leads the global obesity drug market vs Novo Nordisk as competition heats up.
Veeva Systems recently secured Eli Lilly and Company’s commitment to deploy Veeva Vault CRM globally, while also announcing that President and Chief Customer Officer Thomas D. Schwenger will depart in October 2026, to be succeeded by Dan Rizzo as EVP of Sales, Consulting, and Services. These developments arrive as Wall Street analysts anticipate higher upcoming quarterly earnings and revenue for Veeva, highlighting how large client wins and leadership transitions could shape the company’s...
Eli Lilly recently reported strong revenue growth driven by its Mounjaro and Zepbound obesity and diabetes drugs, raised full-year guidance, advanced its next-generation GLP-1 pipeline, and secured UK approval for Foundayo, its once-daily oral GLP-1 pill for weight management and type 2 diabetes. These developments, alongside vaccine research collaborations and ongoing legal action against unauthorized retatrutide sellers, highlight Lilly’s bid to extend its leadership across injectable,...
Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 25.41% on an annualized basis producing an average annual return of 36.72%. Currently, Eli Lilly has a market capitalization of $1.12 trillion.
Mounjaro and Zepbound are widening Lilly's advantage while its next-generation pipeline adds fresh growth options.
Consensus asks Eli Lilly for far less growth than it is delivering, and for margins to keep climbing from a level it only just reached.
Shares recently traded at $1,280 each, so a split wouldn't be surprising.
Kaos Capital wants a “governance reset” to alter the Duchenne cell therapy maker’s strategic course. Elsewhere, Bristol Myers furthered efforts to build an “AI-powered” discovery engine.
Novo Nordisk A/S stays a Buy as oral Wegovy surges and GLP-1 pipeline strengthens; attractive 2028 P/E suggests upsideâclick to read the NVO stock outlook now.
Drugmaker Bristol-Myers Squibb Company (NYSE:BMY) is putting real money behind its confidence in American manufacturing. On August 10, the company said it will spend about $2.3 billion on a new plant in Houston, part of a larger $40 billion U.S. investment pledge. On the very same day, British regulators cleared Eli Lilly and Company (NYSE:LLY)’s […]
Eli Lilly (LLY) shines as a strong-growth stock with explosive earnings, high profitability, and a bullish breakout technical setup.
Eli Lilly stock broke out of a flat base and reached a record high. Its Mounjaro drug sales surged 91% in the second quarter.
Eli Lilly (LLY) is back in focus after the UK's Medicines and Healthcare products Regulatory Agency approved Foundayo, a once daily oral GLP-1 drug for weight management and type 2 diabetes. See our latest analysis for Eli Lilly. The Foundayo approval arrives during a strong run for Eli Lilly’s stock, with a 30 day share price return of 11.63% and a year to date share price return of 18.51%. Over the longer term, total shareholder returns of 82.64% over one year and 136.19% over three years...
Can anyone challenge Eli Lilly in the weight loss space?
Investors took profits after record highs, but Mounjaro and Zepbound continue producing extraordinary growth.
Bryn Talkington picked Horizon Kinetics, Stephanie Link chose Elanco Animal Health, and Jason Snipe recommended Netflix.
Amplitude Therapeutics, a biotechnology company developing trans-amplifying RNA (taRNA) medicines and vaccines, today announced a strategic research collaboration and licensing agreement with Eli Lilly and Company
OmniAb (OABI) analysis: platform scaling via Eli Lilly partnership, milestone-rich revenue outlook, 2026 cash guidance, valuation and catalystsâread now.
The therapeutic target and modality are undisclosed.
- Reuters
The OmniAb Lilly Deal offers up to $370 million in milestones as OABI raises its 2026 cash outlook and shares jump premarket
Eli Lilly’s second quarter was marked by a positive market reaction, despite the company missing Wall Street’s revenue expectations. Management credited growth in key products—especially in cardiometabolic health, oncology, and neuroscience—as drivers of performance. CEO David Ricks pointed to “robust revenue growth across all Key Products and major geographies,” noting the strength of new medicines and expansion in emerging markets. The launch of Foundayo in the U.S. and UAE, along with ongoing
Eli Lilly's shares are near a record high as the company files six lawsuits against alleged illegal sales of its experimental obesity drug, retatrutide. These legal actions aim to protect the drug's future market ahead of its planned U.S. submission in Q1 2027, given its strong Phase 3 efficacy data. The lawsuits are a proactive measure to safeguard its next major franchise, as current revenue drivers Mounjaro and Zepbound already contribute significantly to Lilly's earnings.
The stock continues to look unstoppable.
Lilly's Foundayo records $98M in Q2 sales, while rising prescriptions, broader access and global expansion set the stage for H2 growth
Novo Nordisk's CEO conceded Eli Lilly is gaining market share even as oral Wegovy hits record prescriptions and the stock keeps falling.
Lilly is suing several US companies that are allegedly selling illegal versions of its weight loss candidate, retatrutide.
NVO's GLP-1 pills offer fresh momentum, but Eli Lilly's fast-growing injectable and oral therapies threaten to widen the competitive gap.
Revenue surged 48% on Mounjaro and Zepbound demand, with full-year guidance raised.
Eli Lilly (LLY) has spent 2026 defending its lead in the weight-loss drug market, mostly with injections. That approach is changing. On Aug. 10, Britain's medicines regulator cleared Lilly's new daily pill for both weight management and type 2 diabetes. It was the first approval the drug received ...
A marketing dispute could reshape a crucial competitive advantage
Absci Corporation recently reported second-quarter 2026 results showing a net loss of US$33.21 million, wider than a year ago, while basic and diluted loss per share from continuing operations narrowed to US$0.21. Alongside these figures, Absci highlighted encouraging early Phase 1 data for ABS-201, its prolactin receptor antibody, and a US$40 million investment and development support from Eli Lilly that extend its cash runway into the second half of 2028. Next, we’ll examine how Eli...
Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S. entities selling black-market products in addition to having referred hundreds of bad actors to regulators and law enforcement worldwide. Lilly is also calling on the entities that sellers use to conduct their illegal business—social media and e-commerce platforms, credit card companies, payment processors and shipping and
Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million investment and development support from Eli Lilly tied to the program. See our latest analysis for Absci. Absci’s recent early Phase 1 ABS-201 update and Eli Lilly’s US$40 million commitment arrive after a sharp run, with the share price delivering a 77.55% 90 day return and a 160.66% year to date share price return, alongside a very large 3 year total shareholder...
The company has referred more than 200 sellers and individuals to regulators.
Eli Lilly has filed six lawsuits against US companies for allegedly selling unauthorized versions of its experimental obesity drug, retatrutide. The drugmaker emphasizes that retatrutide has not received FDA approval and carries significant risks. This action is part of Lilly's broader effort to combat copycat versions of its GLP-1 products, which are known for their benefits beyond diabetes, including effects on heart, kidney, sleep apnea, and addiction.
Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.
Eli Lilly (LLY) shows a strong technical breakout setup with a 10/10 rating, tight consolidation, and defined support/resistance levels.
Wegovy pill upside has already played out, leaving the multiple at the European pharma average
Eli Lilly filed six lawsuits against U.S. entities for illegally selling unapproved retatrutide, warning consumers of serious health risks.
